Back to search results
NCT03982160

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Active, Not Recruiting
PHASE4Ages 35–75InterventionalBasic science
The University of Texas at Arlington
~15 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:L-ArgininePlacebo

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Muscle sympathetic nerve activity (MSNA) will be reduced after L-arginine infusion
Measured over 30 minutes

Conditions

Chronic Kidney Disease

Explore related trials

Chronic Kidney Disease

NCT03982160

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Delaware

    Newark, Delawareno site contact published

  • UT Southwestern

    Dallas, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Paul J Fadel, PhD · PRINCIPAL_INVESTIGATOR · University of Texas at Arlington

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.
Men and women 35 to 75 years of age

Exclusion

myocardial infarction
heart failure
anemia (hemoglobin \<8 g/dl)
cancer with current treatment
previous organ transplantation
immunosuppressant therapy
human immunodeficiency virus infection
pregnancy and/or lactating
current tobacco use
taking menopausal drugs (estradiol)
treatment for diabetic neuropathy
resting heart rate ≥ 100 bpm and
systolic blood pressure ≤ 90 mmHg

What this trial measures

  • Muscle sympathetic nerve activity (MSNA) will be reduced after L-arginine infusion30 minutes

    Multiunit postganglionic MSNA will be recorded using standard microneurographic techniques. Briefly, a unipolar tungsten microelectrode will be inserted into muscle fascicles of the peroneal nerve near the fibular head of the right leg. Neural signals will be amplified, filtered (bandwidth, 700-2,000 Hz), rectified, and integrated (time constant, 0.1 s) to obtain mean voltage neurograms (University of Iowa Bioengineering, Iowa City, IA).